Expect a sector-wide lift after Canopy Growth Mettrum deal, says M Partners

The acquisition of Mettrum Health (Mettrum Health Stock Quote, Chart, News: TSXV:MT) by Canopy Growth Corp. (Canopy Growth Corp. Stock Quote, Chart, News: TSX:CGC) shows there may yet be another level to the already stratospheric rise of Canada’s marijuana sector, says M Partners analyst mason Brown.

Late Wednesday, Canopy announced it would acquire peer Mettrum in a deal valued at approximately C$430 million.

“From day one, Canopy Growth has viewed production capacity, brand diversity, and highly-skilled management as the foundational aspects of our business,” said Canopy CEO Bruce Linton. “Mettrum has established a line of cannabis products that work well in a medical context and will transition naturally into a natural and healthy lifestyle market. Their substantial production facilities will add to our growing production platform as we expand to meet the needs of patients, and their experienced personnel will help Canopy Growth drive our vision forward to the next level. Both Canopy Growth and Mettrum have proven themselves with Canadian patients; and together we intend to make our industry-leading product and service offering even stronger, while developing our common hemp objectives.”

Brown says the acquisition is a signal that the party in Canada’s marijuana sector might not be over yet.

“We expect a lift across the sector as Canopy displays that there is still long-term value within the sector despite the run-up in prices over the past few months,” says Brown. “…we highlight how we look at the industry from a long-term perspective and believe that there is still material upside for all players in the space.”

Brown say the deal scales Canopy considerably, giving the LP a more than 40% market share of patients on a pro forma basis.

“The acquisition expands Canopy’s portfolio of cannabis and hemp brands, is expected to realize revenue and cost synergies, and adds ~$27mm in net cash to Canopy’s balance sheet, leaving the company well-funded for expansion on a local and global scale,” says the analyst. “Recall, Canopy Growth acquired a majority ownership position in Groupe Hemp. Integrating Mettrum Originals is expected to solidify Canopy’s position in the hemp market, a valuable play as the hemp market provides marketing and advertising opportunities by getting on the shelves of grocery stores and furthering brand recognition. Canopy expects revenue and cost synergies to occur via cross-selling to customers, given a broader product offering, and improved supply chain management. Before exercise of options and warrants, the acquisition brings Canopy’s cash balance to ~$68mm and positions the company to continue its expansion plans.”

In a research update to clients today, Brown placed his rating and target on Canopy Growth Corp. under review.

Tagged with: cgcmt
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you by GRID stock ahead of Q3 results?

Beacon Securities analyst Gabriel Leung maintained his “Buy” rating and $7.00 target on Tantalus Systems Holdings (Tantalus Systems Holding Stock… [Read More]

9 hours ago

Three Canadian tech stocks that pay a dividend

A dividend yield alone tells investors little about whether a stock deserves a place in their portfolio. In a November… [Read More]

11 hours ago

RBC chops price target on Air Canada

RBC Capital Markets analyst James McGarragle lowered his target on Air Canada (Air Canada Stock Quote, Chart, News, Analysts, Financials… [Read More]

12 hours ago

Hammond Power Solutions: this analyst just raised his price target

Paradigm Capital analyst Razi Hasan raised his target on Hammond Power Solutions (Hammond Power Solutions Stock Quote, Chart, News, Analysts,… [Read More]

14 hours ago

This analyst just slashed his price target on ProMIS Neurosciences

Roth Capital Partners analyst Boobalan Pachaiyappan cut his target on ProMIS Neurosciences (ProMIS Neurosciences Stock Quote, Chart, News, Analysts, Financials… [Read More]

15 hours ago

First Solar stock: Buy, Sell or Hold?

Roth Capital Partners analyst Philip Shen maintained his “Buy” rating and US$300.00 target on First Solar (First Solar, Stock Quote,… [Read More]

16 hours ago